Radiopharmaceuticals and FDA: A clinician's perspective

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Since 1975, the Food and Drug Administration has been primarily responsible for the regulation of all radiopharmaceuticals. The process of new drug approval for radiopharmaceuticals differs from that for any other class of drugs. The slow approval of new radiopharmaceuticals arises from deficiencies in the actions of FDA, radiopharmaceutical manufacturers, and nuclear medicine practitioners.

Original languageEnglish
Pages (from-to)355-360
Number of pages6
JournalMedical Instrumentation
Volume15
Issue number6
StatePublished - Nov 1 1981

Fingerprint

Dive into the research topics of 'Radiopharmaceuticals and FDA: A clinician's perspective'. Together they form a unique fingerprint.

Cite this